Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
UNISUS macitentan dose-comparison study in pulmonary arterial hypertension
jRCT2061200058Phase 3Active, not recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- Jun 2021
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial of macitentan in pulmonary arterial hypertension (PAH) (2 arms), sponsored by Janssen Pharmaceutical. Primary endpoint: Time to first Clinical Events Committee-adjudicated morbidity or mortality event. Started Jun 2021; status: active, not recruiting.
02
Drugs
macitentan
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on jRCT2061200058.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2061200058.